Patents by Inventor Mark Gelfand

Mark Gelfand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11364264
    Abstract: This disclosure is directed to methods of preparing dendritic cells or other CD40 bearing antigen-presenting cells and methods of treating cancer by using the dendritic cells or other antigen-presenting cells in combination with anti-chemorepellant agents. This disclosure is further directed to methods of preparing T cells and methods of treating cancer, by activated T cells optionally in combination with anti-chemorepellant agents. The antigen presenting cells of the disclosure are activated by incubation with cancer cells and fusion proteins. The T cells of the disclosures are activated by incubation with activated antigen-presenting cells that were activated by incubation with cancer cells and a fusion protein. In particular, the fusion protein comprises an antigen-binding domain, e.g., an antibody or antibody fragment, and a stress protein domain.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: June 21, 2022
    Assignee: The General Hospital Corporation
    Inventors: Mark C. Poznansky, Jeffrey A. Gelfand
  • Publication number: 20220176119
    Abstract: An implantable medical device for treating breathing disorders such as central sleep apnea wherein stimulation is provided to the phrenic nerve through a transvenous lead system with the stimulation beginning after inspiration to extend the duration of a breath and to hold the diaphragm in a contracted condition.
    Type: Application
    Filed: March 1, 2022
    Publication date: June 9, 2022
    Inventors: Mark Gelfand, Howard R. Levin, Andrew Halpert
  • Publication number: 20220152302
    Abstract: A fluid therapy method for an ADHF patient includes setting a urine output rate desired threshold, setting one or more desired negative net gain rates, and optionally setting a total fluid loss goal. The urine output of the patient is monitored and fluid is automatically administered to the patient at increasing rates to equal to or approximately match the patient's increasing urine output rates until the patient's urine output rate reaches the set urine output rate desired threshold. Thereafter, fluid is administered to the patient at rates to achieve the set desired negative net gain rate until the fluid loss goal is reached. Thereafter, until the end of therapy, fluid is administered to the patient at rates equal to or approximately equal to the monitored urine output rates.
    Type: Application
    Filed: November 24, 2021
    Publication date: May 19, 2022
    Inventors: Andrew V. HALPERT, Mark TAUSCHER, Mark GELFAND, Howard LEVIN
  • Patent number: 11305119
    Abstract: An implantable medical device for treating breathing disorders such as central sleep apnea wherein stimulation is provided to the phrenic never through a transvenous lead system with the stimulation beginning after inspiration to extend the duration of a breath and to hold the diaphragm in a contracted condition.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: April 19, 2022
    Assignee: ZOLL RESPICARDIA, INC.
    Inventors: Mark Gelfand, Howard R. Levin, Andrew Halpert
  • Patent number: 11305114
    Abstract: A system for treating disordered breathing of a human being includes an implantable transvenous stimulation lead having at least one stimulation electrode and a sensor configured to detect activity level of the human being. The system includes an energy source, a pulse generator and circuitry, the circuitry operative to receive a signal indicative of the activity level of the human being from the sensor, wherein the circuitry is configured to cause the energy source and the pulse generator to deliver spaced apart stimulation signals to the at least one stimulation electrode while the activity level of the human being is sufficiently low to be indicative of sleep. Spaced apart stimulation pulses from the electrode are configured to extend a duration of a time of at least one breath being defined as the time from an onset of inhalation to the onset of inhalation of a successive breath.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: April 19, 2022
    Assignee: ZOLL RESPICARDIA, INC.
    Inventors: Mark Gelfand, Howard Levin, Andrew Halpert, Antonis Panteleon
  • Publication number: 20220111202
    Abstract: A means for treating breathing disorders by stimulating respiratory muscles or nerves to entrain respiratory systems while leaving respiratory drive intact. Embodiments of the invention employ frequency analysis to determine if appropriate stimulation energy is being applied.
    Type: Application
    Filed: June 17, 2021
    Publication date: April 14, 2022
    Inventors: Mark Gelfand, Kristofer J. James, Randy W. Westlund, Antonis Panteleon, Todd P. Goblish, Mark C. Lynn
  • Publication number: 20220008725
    Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.
    Type: Application
    Filed: June 29, 2021
    Publication date: January 13, 2022
    Inventors: Howard Levin, Mark Gelfand
  • Publication number: 20220000545
    Abstract: A method for treating a heart failure patient by ablating a nerve of the splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method including: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects.
    Type: Application
    Filed: February 9, 2021
    Publication date: January 6, 2022
    Inventors: Howard LEVIN, Mark GELFAND
  • Patent number: 11213621
    Abstract: A fluid therapy method for an ADHF patient includes setting a urine output rate desired threshold, setting one or more desired negative net gain rates, and optionally setting a total fluid loss goal. The urine output of the patient is monitored and fluid is automatically administered to the patient at increasing rates to equal to or approximately match the patient's increasing urine output rates until the patient's urine output rate reaches the set urine output rate desired threshold. Thereafter, fluid is administered to the patient at rates to achieve the set desired negative net gain rate until the fluid loss goal is reached. Thereafter, until the end of therapy, fluid is administered to the patient at rates equal to or approximately equal to the monitored urine output rates.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: January 4, 2022
    Assignee: Reprieve Cardiovascular, Inc.
    Inventors: Andrew V. Halpert, Mark Tauscher, Mark Gelfand, Howard Levin
  • Publication number: 20210393326
    Abstract: A method for treating a heart failure patient by ablating a nerve of the splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method including: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects.
    Type: Application
    Filed: September 2, 2021
    Publication date: December 23, 2021
    Inventors: Howard LEVIN, Mark GELFAND
  • Publication number: 20210330378
    Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Application
    Filed: July 1, 2021
    Publication date: October 28, 2021
    Inventors: Denise Zarins, Hanson Gifford, III, Mark E. Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Patent number: 11154354
    Abstract: Apparatuses and methods for treating a heart failure patient by ablating a nerve of the thoracic splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method comprising: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying stimulation energy after the ablation and observing hemodynamic effects and monitoring for presence of the lung in the ablation zone. An alternative method comprising: inserting a catheter into a vein adjacent the nerve, detecting that lung tissue is a safe distance from an ablation zone, and delivering ablation energy to the target nerve when lung tissue is a safe distance from the ablation zone.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: October 26, 2021
    Assignee: Axon Therapies, Inc.
    Inventors: Howard Levin, Mark Gelfand, Zoar Jacob Engelman, Dorin Panescu, Mark S. Leung
  • Publication number: 20210298826
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Application
    Filed: June 14, 2021
    Publication date: September 30, 2021
    Inventors: Mark E. Deem, Hanson S. Gifford, III, Denise Zarins, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
  • Patent number: 11129674
    Abstract: Microwave catheter apparatuses, systems, and methods for achieving renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a catheter treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver a microwave transmission element to a renal artery via an intravascular path. Renal neuromodulation may be achieved via dielectric heating in the presence of microwave irradiation that modulates neural fibers that contribute to renal function or alters vascular structures that feed or perfuse the neural fibers.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: September 28, 2021
    Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
    Inventors: Karun D. Naga, Roman Turovskiy, Denise Zarins, Mark Gelfand, Arye Rosen
  • Publication number: 20210267682
    Abstract: Microwave catheter apparatuses, systems, and methods for achieving renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a catheter treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver a microwave transmission element to a renal artery via an intravascular path. Renal neuromodulation may be achieved via dielectric heating in the presence of microwave irradiation that modulates neural fibers that contribute to renal function or alters vascular structures that feed or perfuse the neural fibers.
    Type: Application
    Filed: May 19, 2021
    Publication date: September 2, 2021
    Inventors: Karun D. Naga, Roman Turovskiy, Denise Zarins, Mark Gelfand, Arye Rosen
  • Patent number: 11083894
    Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: August 10, 2021
    Assignee: BackBeat Medical, LLC
    Inventors: Howard Levin, Mark Gelfand
  • Publication number: 20210236727
    Abstract: A apparatus and method to treat patients with acute decompensated heart failure (ADHF), heart failure or another fluid overload condition, that includes: administrating a diuretic to the patient to increase urine output of the patient; monitoring a rate or amount of urine output by the patient after administration of the diuretic; infusing a hydration liquid into the patient to induce an increase in the urine output; and adjusting the rate or amount of the hydration liquid infused into the patient to achieve a target fluid loss in the patient.
    Type: Application
    Filed: May 16, 2019
    Publication date: August 5, 2021
    Inventors: Howard R. Levin, Andrew Halpert, Zoar Engelman, Mark Gelfand
  • Patent number: 11065443
    Abstract: A means for treating breathing disorders by stimulating respiratory muscles or nerves to entrain respiratory systems while leaving respiratory drive intact. Embodiments of the invention employ frequency analysis to determine if appropriate stimulation energy is being applied.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: July 20, 2021
    Assignee: Zoll Respicardia, Inc.
    Inventors: Mark Gelfand, Kristofer J. James, Randy W. Westlund, Antonis Panteleon, Todd P. Goblish, Mark C. Lynn
  • Patent number: 11033328
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: June 15, 2021
    Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
    Inventors: Mark E. Deem, Hanson Gifford, III, Denise Zarins, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
  • Publication number: 20210169632
    Abstract: Endobronchial methods, devices and systems for treating emphysema by creating an airway bypass in a patient's airway including a longitudinal fenestration held open by an airway expander.
    Type: Application
    Filed: November 30, 2018
    Publication date: June 10, 2021
    Inventors: Qi LI, Don TANAKA, Lilip LAU, Mark GELFAND